ADMA Biologics Class Action Lawsuit Establishes August 10 Deadline for Investors
Investors with losses exceeding $100,000 in ADMA Biologics securities must file forlead plaintiff status by August 10 in a class action lawsuit concerning alleged securities law violations.
New Orleans, LA – July 24, 2026 – Investors who incurred losses of over $100,000 in ADMA Biologics, Inc. (NasdaqGM: ADMA) securities have until August 10, 2026, to apply for lead plaintiff status in a class action lawsuit. This applies to investors who purchased or acquired the company's securities between August 9, 2024, and March 25, 2026.
The lawsuit, filed in the U.S. District Court for the District of New Jersey, alleges that ADMA Biologics and certain executives failed to disclose material information, violating federal securities laws. The complaint claims the company engaged in an undisclosed related-party transaction, used "channel stuffing" to artificially inflate revenue, and lacked adequate internal controls.
These alleged misrepresentations and omissions created a situation where ADMA Biologics' statements about its business and prospects were materially false and misleading. The law firm Kahn Swick & Foti, LLC is available to discuss legal options with affected investors.
ClaimsFiler, a shareholder information service, facilitates investor recovery in securities class action settlements by providing access to case details and claim submission portals.